Search the Newsreel

Mira Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Mira Pharmaceuticals (MIRA) announced that it received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement. The company's stock has traded below $1.00 for 30 consecutive business days, and it now has 180 days until January 25, 2027, to regain …

Liquidity Mapping Around (MIRM) Price Events

Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) is showing weak near and mid-term sentiment, despite a positive long-term outlook. AI models have generated three distinct trading strategies for MIRM, including position trading, momentum breakout, and risk hedging, with detailed entry points, targets, and stop losses. The …

The Scotts Miracle-Gro Company 2026 Q3 - Results - Earnings Call Presentation (NYSE:SMG) 2026-07-31

The Scotts Miracle-Gro Company Q3 2026 Earnings Call Summary - Moby Strategic Shift and Operational Progress Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. …

Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis

This article analyzes the valuation of Telomir Pharmaceuticals Inc (TELO), highlighting its current valuation score of 6.89, which ranks 142 out of 155 in the Pharmaceuticals industry. The company's P/E ratio is reported as -4.39, indicating it is significantly below its recent high and …

Mirion Technologies (MIR) Stock Falls As Acquisitions Mask Modest Organic Growth

Mirion Technologies (MIR) stock fell by 1.7% to US$14.30 despite expanding margins and strong free cash flow, as the company's Q2 2026 earnings revealed that acquisitions heavily drove its 20% top-line growth, with organic revenue at only 1%. Investors remain cautious due to concerns …

Mirion Technologies (NYSE: MIR) Q2 2026 revenue reaches $266.8M

Mirion Technologies reported Q2 2026 revenue of $266.8 million, an increase from $222.9 million in Q2 2025, driven by higher product and service sales, particularly in its Nuclear & Safety segment, and recent acquisitions. Despite a slight decrease in net income attributable to Mirion …

Hear Mirum Pharmaceuticals' second-quarter update Aug. 5

Mirum Pharmaceuticals (Nasdaq: MIRM) announced it will report its second-quarter 2026 financial results on August 5, 2026. The company will also host a conference call on the same day to discuss these results and recent corporate developments. Mirum Pharmaceuticals is a rare disease company …

MIRA Pharmaceuticals advances non-opioid pain and obesity drug candidates toward IND-enabling studies.

MIRA Pharmaceuticals has successfully advanced its two primary drug candidates, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction disorders, through key preclinical development phases. These stages included optimizing formulation, manufacturing, and conducting exploratory toxicology studies. The company is now preparing to …

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

MIRA Pharmaceuticals announced significant progress in the development of its two lead preclinical programs, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction-related disorders. The company has completed 7-day toxicology and pharmacokinetic studies, alongside formulation optimization, CMC activities, and manufacturing development. These …

MIRA's Two Oral Drug Candidates Finish Dosing in Rats and Dogs

MIRA Pharmaceuticals announced that its two lead preclinical programs, MIRA-55 (for chronic inflammatory pain) and SKNY-1 (for obesity and addiction-related disorders), have completed the dosing phase of exploratory 7-day toxicology studies in rats and dogs. This advancement, alongside formulation optimization and manufacturing activities, moves …

MIRA Pharmaceuticals completes toxicology studies for two candidates

MIRA Pharmaceuticals (NASDAQ:MIRA) announced the completion of 7-day toxicology and pharmacokinetic studies for its two preclinical drug candidates, MIRA-55 and SKNY-1. MIRA-55 is being developed for chronic inflammatory pain, while SKNY-1 is for obesity and addiction-related disorders. The company is advancing both programs through …

Miramar Resources Insiders Lose Out As Stock Sinks To AU$0.002

Scotts Miracle Gro (SMG) Stock Price Reflects Debt Fears Over Margin Gains

Regina Miracle Details Planned Re-Appointment and Audit Fee for PwC

Mirum Pharmaceuticals Inc (MIRM) Valuation: PE, PB & Fair Value Analysis

Mirum Pharmaceuticals Inc (MIRM) has a current valuation score of 9.66, placing it 11th out of 155 companies in the Pharmaceuticals industry. Its P/E ratio is -7.91, which is below its recent high and above its recent low. However, relevant data for P/B, P/S, …

ScottsMiracle-Gro Announces Speakers and Other Details for its Investor Day on August 4, 2026

The Scotts Miracle-Gro Company (NYSE: SMG) has announced details for its Investor Day, scheduled for Tuesday, August 4, 2026, at the New York Stock Exchange. The event will feature presentations and Q&A sessions with key executives, focusing on SMG's 2.0 growth strategy, capital allocation, …

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Mirum Pharmaceuticals (Nasdaq: MIRM) will announce its second-quarter 2026 financial results on August 5, 2026. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results and recent corporate developments. Mirum is a rare disease …

Mirion Technologies Inc (MIR) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and ...

Mirum Pharmaceuticals Q2 Results: Earnings call set for Aug 5, 2026

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) will release its Q2 2026 financial results on August 5, 2026, followed by a conference call at 4:30 p.m. ET to discuss the quarterly figures and recent corporate progress. The rare disease company will provide investors with insights into …

The Scotts Miracle Gro Co (SMG) Q3 2026 Earnings Call Highlights: Strong Sales Growth Amid Cost ...

This article first appeared on GuruFocus. Total Company Net Sales: Increased 1% to $1.17 billion in Q3; year-to-date increased 2% to $2.99 billion. US Consumer Business Net Sales: Increased 2% year-to-date to $2.74 billion. Branded Product Sales Growth: Up 4.5% year-to-date. Gross Margin Rate: …

Scotts Miracle-Gro Is Positioned for Long-Term US Gardening Growth

Scotts Miracle-Gro, a leading company in the US consumer lawn and gardening market, is positioned for long-term growth. The company provides a wide range of products for lawncare and gardening. This report highlights their business strategy and outlook, despite recent news of the CEO …

Mirum Pharmaceuticals earnings in focus as pipeline expands

Mirum Pharmaceuticals is poised to report its second-quarter earnings, with analysts anticipating a significant sequential improvement in both revenue and a reduced loss per share. Investors will be closely watching the company's progress towards its full-year revenue guidance, the commercial performance of LIVMARLI, and …

Scotts Miracle-Gro (SMG) Tops Q3 Earnings Estimates

Scotts Miracle-Gro (SMG) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.53 per share. This compares to earnings of $2.59 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Scotts (SMG) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, Scotts Miracle-Gro (SMG) reported revenue of $1.17 billion, down 1.3% over the same period last year. EPS came in at $2.82, compared to $2.59 in the year-ago quarter. The reported revenue represents a surprise of -0.17% over the …

ScottsMiracle-Gro Reports Third Quarter Results; Updates Full-Year Outlook Reflecting Accelerated EPS Growth

Scotts Miracle-Gro Company (The) Company raises its full-year non-GAAP adjusted EPS from continuing operations guidance to $4.30 to $4.45, up from the prior guidance of $4.15 to $4.35 MARYSVILLE, Ohio, July 29, 2026 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the leading …

Mira Pharmaceuticals Inc (MIRA) Institutional Confidence

This article provides an analysis of Mira Pharmaceuticals Inc (MIRA) institutional confidence score, which currently stands at 3.00 with no change since the previous score. It details the shares held by various institutional investors, including Bay Shore Trust, McNulty (Brian Patrick), and Geode Capital …

Scotts Miracle-Gro: Post-Earnings Sell-Off Is A Buying Opportunity (NYSE:SMG)

Scotts Miracle-Gro (NYSE:SMG) Announces Quarterly Earnings Results, Beats Expectations By $0.34 EPS

Mirion Technologies, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:MIR) 2026-07-29

* Mirion Technologies (MIR [https://seekingalpha.com/symbol/MIR]) is scheduled to announce Q2 earnings results on Tuesday, July 28th, after market close. * The consensus EPS Estimate is $0.10 [https://seekingalpha.com/symbol/MIR/earnings/estimates] (-9.1% Y/Y) and the consensus Revenue Estimate is $269.63M (+21.0% Y/Y). * Over the last 2 years, …

Jammu & Kashmir Bank Q1 result: Net profit falls 11.5% to ₹428.8 crore

Mirvac Group (ASX:MGR) Shares Rally: What Are Investors Watching Beyond the Day’s Market Move?

Here's What Key Metrics Tell Us About Mirion Technologies (MIR) Q2 Earnings

For the quarter ended June 2026, Mirion Technologies, Inc. (MIR) reported revenue of $266.8 million, up 19.7% over the same period last year. EPS came in at $0.12, compared to $0.11 in the year-ago quarter. The reported revenue represents a surprise of -1.81% over …

Mirion Technologies, Inc. (MIR) Q2 Earnings Beat Estimates

Mirion Technologies, Inc. (MIR) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.11 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents …

Mirion (NYSE:MIR) Misses Q2 CY2026 Sales Expectations

Mirion (NYSE:MIR) Misses Q2 CY2026 Sales Expectations Radiation safety company Mirion (NYSE:MIR) fell short of the market's revenue expectations in Q2 CY2026, but sales rose 19.7% year on year to $266.8 million. Its non-GAAP profit of $0.12 per share was 17% above analysts' consensus …

Scotts Miracle-Gro declares $0.66 dividend

* Scotts Miracle-Gro (SMG [https://seekingalpha.com/symbol/SMG]) declares $0.66/share quarterly dividend [https://seekingalpha.com/pr/20598398-the-scotts-miracle-gro-company-announces-quarterly-dividend-payment], in line with previous. * Forward yield [https://seekingalpha.com/symbol/SMG/dividends/yield?source=news_bullet] 3.6% * Payable Sept. 4; for shareholders of record Aug. 21; ex-div Aug. 21. * See SMG Dividend Scorecard, Yield Chart, & Dividend Growth. [https://seekingalpha.com/symbol/SMG/dividends?source=news_bullet] MORE …

Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ: TELO) Stock Price, News & Analysis

This article provides a detailed financial overview and news analysis for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), including its current stock price, key financials, income statements, balance sheets, cash flow, and peer comparison. It also offers a company profile highlighting its focus on developing therapeutic …